NCT03450798

Brief Summary

Peripheral nerve block is an ideal choice for lower limb surgery because of the peripheral site of the surgical procedure and the ability to block pain pathways at multiple levels. On the contrary to other anesthetic techniques, as spinal or general anesthesia, properly performed peripheral nerve blocks bypass adverse events as hemodynamic instability and respiratory complications, properly treat post-operative pain leading to early hospital discharge. Additional advantages of peripheral nerve blocks are that they can be used in patients receiving anti-coagulants or lumbosacral disease in addition to avoidance of airway instrumentation. Recently, there has been a significant interest in regional anesthesia and peripheral nerve blockade. This is facilitated by a significant advance of the research in this field and availability of better equipment facilitating regional anesthesia.The aim of this study was to assess the efficacy and safety of SOFT block (sciatic-obturator-femoral nerve block technique) in comparison with spinal anesthesia in patients undergoing surgery for fixation of open tibial fractures using Ilizarov external fixator.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
107

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 10, 2018

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

February 20, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 1, 2018

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 10, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2019

Completed
Last Updated

January 24, 2019

Status Verified

January 1, 2019

Enrollment Period

11 months

First QC Date

February 20, 2018

Last Update Submit

January 22, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • T- test of the recovery time(duration of analgesia)mean±SD

    It is the time from the end of local anaesthetic injection to complete resolution of sensory block

    3-12 hours

Secondary Outcomes (2)

  • Review of medical records for postoperative complications

    48 hours after the procedure

  • Failure of the block

    50 minutes

Study Arms (2)

SOFT block group

ACTIVE COMPARATOR

needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected

Device: SOFT block group

spinal anesthesia group

SHAM COMPARATOR

patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.

Device: spinal anesthesia group

Interventions

needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected

SOFT block group

patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.

spinal anesthesia group

Eligibility Criteria

Age35 Years - 57 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • to 57 years old
  • ASA I,II
  • BMI\<30
  • fixation of open tibial fractures using Ilizarov external fixator -

You may not qualify if:

  • Refusal to participate,
  • Inability to communicate with the investigators or hospital staff,
  • body mass index\>40 kg/m2
  • patients undergoing bilateral surgery,
  • History of coagulopathies
  • creatinine\>1.5 mg/dL
  • American Society of Anesthesia (ASA) III-IV
  • Any contraindication to regional anesthesia
  • Unstable vital data
  • Head or chest trauma will be excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain shams university

Cairo, 11566, Egypt

Location

Related Publications (1)

  • Shokri H, Kasem AA. Sciatic obturator femoral technique versus spinal anaesthesia in patients undergoing surgery for fixation of open tibial fractures using Ilizarov external fixator. A randomised trial. BMC Anesthesiol. 2020 Jan 4;20(1):4. doi: 10.1186/s12871-019-0920-6.

MeSH Terms

Conditions

Acute Pain

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Hoda Shokri, MD

    Ain Shams University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
HShokri

Study Record Dates

First Submitted

February 20, 2018

First Posted

March 1, 2018

Study Start

February 10, 2018

Primary Completion

January 10, 2019

Study Completion

January 10, 2019

Last Updated

January 24, 2019

Record last verified: 2019-01

Data Sharing

IPD Sharing
Will share

study protocol

Shared Documents
STUDY PROTOCOL
Time Frame
5 to 6 months
Access Criteria
The collected data are coded, tabulated, and statistically analyzed using statistical package for social sciences software, version 17.0 (SPSS Inc., Chicago, Illinois, USA). Descriptive statistics are carried out for numerical parametric data and presented as mean±SD, whereas categorical data are presented as number and percentage. Variables such as demographic data and comorbidities are compared using the χ2-test. A P value less than 0.05 was considered significant.

Locations